Key result
Clozapine-induced myocarditis is a potentially severe complication requiring slow individualized titration, close monitoring of CRP and troponin, and prompt discontinuation upon diagnosis.
Why the study?
Clozapine-induced myocarditis has potentially severe outcomes, but the mechanism behind its lethality remains unclear and lacks a widely accepted consensus or treatment guideline.
This review highlights the mechanisms, clinical features, and monitoring strategies for clozapine-induced myocarditis, emphasizing the need for standardized global guidelines to manage this potentially fatal adverse effect.
Emphasizes myocarditis vigilance with clozapine; leaves open standardized global guidelines pending prospective validation.
Currently, the treatment of schizophrenia remains primarily pharmacological, with approximately 30% of patients diagnosed with treatment-resistant schizophrenia (TRS). Clozapine continues to be the first choice treatment for this subgroup of patients. As the preferred treatment, clozapine offers clear advantages in efficacy; however, its complex and troublesome adverse effects pose significant challenges for psychiatrists. Common side effects include granulocytopenia, intestinal obstruction, myocarditis, cardiomyopathy, constipation, and seizures. The first two complications are easier to manage due to the availability of laboratory monitoring, and improved management strategies are now in place in clinical practice. In recent years, clozapine-induced myocarditis (CIM) has gained considerable attention because of its potentially severe outcomes. However, the mechanism behind its lethality remains unclear, and there is no widely accepted consensus or treatment guideline, which complicates the implementation of targeted prevention in clinical practice. This review aims to summarize the clinical manifestations of CIM, explore the underlying mechanisms, and discuss recent advances in monitoring, diagnosis, and treatment, with the goal of offering constructive recommendations for future clinical management.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a review in Clozapine-Induced Myocarditis. Clozapine was evaluated. Clozapine-induced myocarditis is a potentially severe complication requiring slow individualized titration, close monitoring of CRP and troponin, and prompt discontinuation upon diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: